TBPH
Theravance Biopharma, Inc.
Price Chart
Latest Quote
$16.58
-0.13 (-0.78%)
Current Price
| Previous Close | $16.71 |
| Open | $16.72 |
| Day High | $16.83 |
| Day Low | $16.55 |
| Volume | 792,334 |
Stock Information
| Shares Outstanding | 51.55M |
| Total Debt | $40.50M |
| Cash Equivalents | $394.67M |
| Revenue | $109.78M |
| Net Income | $114.54M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $854.75M |
| P/E Ratio | 7.43 |
| EPS (TTM) | $2.23 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $506.26M |
| Sales | $109.78M |
| Income | $114.54M |
| Book/sh | $5.64 |
| Cash/sh | $7.66 |
| Employees | 90 |
Financial Ratios
| Quick Ratio | 12.91 |
| Current Ratio | 13.14 |
| Debt/Eq | 13.94 |
Returns & Margins
| ROA | 0.76% |
| ROE | 50.17% |
| Gross Margin | 71.04% |
| Operating Margin | -33.05% |
| Profit Margin | 104.34% |
Ownership
| Insider Ownership | 4.64% |
| Institutional Ownership | 99.21% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 13.21 |
| P/S | 7.79 |
| P/B | 2.94 |
Analyst Data
| Recommendation | none |
| Target Price | $17.40 |
Technical Indicators
| SMA20 | $16.32 |
| SMA50 | $16.51 |
| SMA200 | $16.64 |
| RSI | 59.35 |
| ATR | 0.3545 |
| Shares Float | 23.70M |
| Short Float | 15.66% |
| Short Ratio | 14.52 |
| Volatility | 0.18 |
| Rel Volume | 2.14 |
Performance History
| Week | +0.55% |
| Month | +2.03% |
| Quarter | +18.34% |
| 6 Months | -5.42% |
| YTD | -8.65% |
| Year | +56.42% |
| 3 Years | +54.66% |
| 5 Years | -8.90% |
| 10 Years | -27.53% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $16.58 | 829,445 |
| 2026-06-17 | $16.71 | 424,400 |
| 2026-06-16 | $16.69 | 340,500 |
| 2026-06-15 | $16.32 | 346,300 |
| 2026-06-12 | $16.64 | 230,200 |
| 2026-06-11 | $16.49 | 289,900 |
| 2026-06-10 | $16.37 | 341,200 |
| 2026-06-09 | $16.49 | 332,100 |
| 2026-06-08 | $16.29 | 227,100 |
| 2026-06-05 | $16.29 | 242,800 |
| 2026-06-04 | $16.37 | 409,800 |
| 2026-06-03 | $15.92 | 335,100 |
| 2026-06-02 | $15.58 | 814,800 |
| 2026-06-01 | $15.94 | 392,200 |
| 2026-05-29 | $16.06 | 531,200 |
| 2026-05-28 | $16.21 | 358,800 |
| 2026-05-27 | $16.26 | 322,300 |
| 2026-05-26 | $16.41 | 434,100 |
| 2026-05-22 | $16.37 | 277,600 |
| 2026-05-21 | $16.34 | 269,400 |
| 2026-05-20 | $16.55 | 476,500 |
| 2026-05-19 | $16.25 | 313,800 |
About Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
đ° Latest News
Are Options Traders Betting on a Big Move in Theravance Biopharma Stock?
Zacks âĸ 2026-05-13T13:27:00Z
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
Zacks âĸ 2026-05-08T17:26:00Z
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-06T21:10:03Z
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised
Zacks âĸ 2026-05-01T15:15:00Z
Laughing Water Capitalâs New Position: Theravance Biopharma (TBPH)
Insider Monkey âĸ 2026-04-24T14:27:11Z
B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14
Insider Monkey âĸ 2026-04-20T00:09:42Z
Theravance Stock Declines Around 17% in Three Months: Here's Why
Zacks âĸ 2026-04-16T17:13:00Z
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics
Zacks âĸ 2026-04-06T15:10:00Z
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
Zacks âĸ 2026-04-02T14:00:00Z
Theravance's Q4 Earnings and Revenues Miss Estimates
Zacks âĸ 2026-03-20T18:45:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $107,464,000 | $64,381,000 | $57,424,000 | $51,346,000 |
| Operating Revenue | $107,464,000 | $64,381,000 | $57,424,000 | $51,346,000 |
| Expenses | ||||
| Interest Expense | $2,461,000 | $2,546,000 | $2,350,000 | $6,369,000 |
| Total Expenses | $111,066,000 | $106,817,000 | $110,716,000 | $130,465,000 |
| Other Income Expense | $125,137,000 | $-4,513,000 | $-2,743,000 | $-15,872,000 |
| Other Non Operating Income Expenses | $50,000,000 | - | - | - |
| Net Non Operating Interest Income Expense | $7,712,000 | $2,335,000 | $6,766,000 | $2,176,000 |
| Interest Expense Non Operating | $2,461,000 | $2,546,000 | $2,350,000 | $6,369,000 |
| Operating Expense | $111,066,000 | $106,817,000 | $110,716,000 | $130,465,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $105,895,000 | $-56,418,000 | $-55,193,000 | $-92,824,000 |
| Net Interest Income | $7,712,000 | $2,335,000 | $6,766,000 | $2,176,000 |
| Interest Income | $10,173,000 | $4,881,000 | $9,116,000 | $8,545,000 |
| Normalized Income | $44,335,256 | $-52,852,730 | $-53,026,030 | $-80,285,120 |
| Net Income From Continuing And Discontinued Operation | $105,895,000 | $-56,418,000 | $-55,193,000 | $872,132,000 |
| Total Operating Income As Reported | $-3,602,000 | $-46,949,000 | $-56,035,000 | $-91,957,000 |
| Net Income Common Stockholders | $105,895,000 | $-56,418,000 | $-55,193,000 | $872,132,000 |
| Net Income | $105,895,000 | $-56,418,000 | $-55,193,000 | $872,132,000 |
| Net Income Including Noncontrolling Interests | $105,895,000 | $-56,418,000 | $-55,193,000 | $872,132,000 |
| Net Income Continuous Operations | $105,895,000 | $-56,418,000 | $-55,193,000 | $-92,824,000 |
| Pretax Income | $129,247,000 | $-44,614,000 | $-49,269,000 | $-92,815,000 |
| Special Income Charges | $75,137,000 | $-4,513,000 | $-2,743,000 | $-15,872,000 |
| Interest Income Non Operating | $10,173,000 | $4,881,000 | $9,116,000 | $8,545,000 |
| Operating Income | $-3,602,000 | $-42,436,000 | $-53,292,000 | $-79,119,000 |
| Net Income Discontinuous Operations | - | - | $0 | $964,956,000 |
| Earnings From Equity Interest | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $2.06 | $-1.15 | $-1.00 | $11.85 |
| Basic EPS | $2.10 | $-1.15 | $-1.00 | $11.85 |
| Other | ||||
| Tax Effect Of Unusual Items | $13,577,256 | $-947,730 | $-576,030 | $-3,333,120 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $59,382,000 | $-33,940,000 | $-39,920,000 | $-63,550,000 |
| Total Unusual Items | $75,137,000 | $-4,513,000 | $-2,743,000 | $-15,872,000 |
| Total Unusual Items Excluding Goodwill | $75,137,000 | $-4,513,000 | $-2,743,000 | $-15,872,000 |
| Reconciled Depreciation | $2,811,000 | $3,615,000 | $4,256,000 | $7,024,000 |
| EBITDA (Bullshit earnings) | $134,519,000 | $-38,453,000 | $-42,663,000 | $-79,422,000 |
| EBIT | $131,708,000 | $-42,068,000 | $-46,919,000 | $-86,446,000 |
| Diluted Average Shares | $51,507,000 | $48,847,000 | $55,303,000 | $73,591,000 |
| Basic Average Shares | $50,317,000 | $48,847,000 | $55,303,000 | $73,591,000 |
| Diluted NI Availto Com Stockholders | $105,895,000 | $-56,418,000 | $-55,193,000 | $872,132,000 |
| Tax Provision | $23,352,000 | $11,804,000 | $5,924,000 | $9,000 |
| Gain On Sale Of Ppe | $75,137,000 | $0 | - | - |
| Impairment Of Capital Assets | $0 | $4,513,000 | $0 | - |
| Research And Development | $37,414,000 | $37,643,000 | $40,621,000 | $63,392,000 |
| Selling General And Administration | $73,652,000 | $69,174,000 | $70,095,000 | $67,073,000 |
| Restructuring And Mergern Acquisition | - | $0 | $2,743,000 | $12,838,000 |
| Other Special Charges | - | - | - | $3,034,000 |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $296,723,000 | $175,545,000 | $212,995,000 | $441,800,000 |
| Total Assets | $485,570,000 | $354,161,000 | $381,999,000 | $607,400,000 |
| Total Non Current Assets | $67,110,000 | $193,094,000 | $248,458,000 | $253,936,000 |
| Other Non Current Assets | $25,716,000 | $157,322,000 | $203,103,000 | $201,935,000 |
| Investmentin Financial Assets | $11,128,000 | $0 | - | - |
| Current Assets | $418,460,000 | $161,067,000 | $133,541,000 | $353,464,000 |
| Other Current Assets | $7,564,000 | $4,277,000 | $11,603,000 | $7,682,000 |
| Receivables | $95,539,000 | $68,440,000 | $17,474,000 | $16,785,000 |
| Other Receivables | $50,000,000 | $50,000,000 | - | - |
| Accounts Receivable | $45,539,000 | $18,440,000 | $17,474,000 | $16,785,000 |
| Cash Cash Equivalents And Short Term Investments | $315,357,000 | $88,350,000 | $102,426,000 | $327,484,000 |
| Cash And Cash Equivalents | $167,806,000 | $37,797,000 | $39,545,000 | $298,172,000 |
| Prepaid Assets | - | $73,000 | $2,038,000 | $1,513,000 |
| Debt | ||||
| Total Debt | $42,703,000 | $49,820,000 | $49,159,000 | $52,160,000 |
| Long Term Debt And Capital Lease Obligation | $31,758,000 | $39,108,000 | $45,236,000 | $45,407,000 |
| Current Debt And Capital Lease Obligation | $10,945,000 | $10,712,000 | $3,923,000 | $6,753,000 |
| Net Debt | - | - | - | - |
| Long Term Debt | - | - | - | - |
| Current Debt | - | - | - | - |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $188,847,000 | $178,616,000 | $169,004,000 | $165,600,000 |
| Total Non Current Liabilities Net Minority Interest | $150,545,000 | $146,531,000 | $144,237,000 | $136,885,000 |
| Other Non Current Liabilities | $33,108,000 | $32,224,000 | $33,707,000 | $27,095,000 |
| Tradeand Other Payables Non Current | $85,679,000 | $75,199,000 | $65,294,000 | $64,191,000 |
| Current Liabilities | $38,302,000 | $32,085,000 | $24,767,000 | $28,715,000 |
| Payables And Accrued Expenses | $27,357,000 | $21,373,000 | $20,844,000 | $21,962,000 |
| Payables | $7,855,000 | $8,095,000 | $8,014,000 | $1,554,000 |
| Total Tax Payable | $5,287,000 | $5,853,000 | $0 | - |
| Income Tax Payable | $5,287,000 | $5,853,000 | $0 | - |
| Accounts Payable | $2,568,000 | $2,242,000 | $1,524,000 | $1,554,000 |
| Non Current Deferred Liabilities | - | - | $0 | $192,000 |
| Other Payable | - | - | $6,490,000 | - |
| Current Deferred Liabilities | - | - | - | $24,000 |
| Interest Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $296,723,000 | $175,545,000 | $212,995,000 | $441,800,000 |
| Total Equity Gross Minority Interest | $296,723,000 | $175,545,000 | $212,995,000 | $441,800,000 |
| Stockholders Equity | $296,723,000 | $175,545,000 | $212,995,000 | $441,800,000 |
| Gains Losses Not Affecting Retained Earnings | $61,000 | $7,000 | $-65,000 | $-15,000 |
| Other Equity Adjustments | $61,000 | $7,000 | $-65,000 | $-15,000 |
| Retained Earnings | $-859,627,000 | $-965,522,000 | $-909,104,000 | $-853,911,000 |
| Long Term Equity Investment | - | - | - | $0 |
| Other | ||||
| Ordinary Shares Number | $51,068,545 | $49,471,000 | $48,091,000 | $65,227,000 |
| Share Issued | $51,068,545 | $49,471,000 | $48,091,000 | $65,227,000 |
| Tangible Book Value | $296,723,000 | $175,545,000 | $212,995,000 | $441,800,000 |
| Invested Capital | $296,723,000 | $175,545,000 | $212,995,000 | $441,800,000 |
| Working Capital | $380,158,000 | $128,982,000 | $108,774,000 | $324,749,000 |
| Capital Lease Obligations | $42,703,000 | $49,820,000 | $49,159,000 | $52,160,000 |
| Total Capitalization | $296,723,000 | $175,545,000 | $212,995,000 | $441,800,000 |
| Additional Paid In Capital | $1,156,288,000 | $1,141,060,000 | $1,122,164,000 | $1,295,725,000 |
| Capital Stock | $1,000 | $0 | $0 | $1,000 |
| Common Stock | $1,000 | $0 | $0 | $1,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $31,758,000 | $39,108,000 | $45,236,000 | $45,407,000 |
| Current Capital Lease Obligation | $10,945,000 | $10,712,000 | $3,923,000 | $6,753,000 |
| Current Accrued Expenses | $19,502,000 | $13,278,000 | $12,830,000 | $20,408,000 |
| Investments And Advances | $11,128,000 | $0 | - | $0 |
| Available For Sale Securities | $11,128,000 | - | - | - |
| Net PPE | $30,266,000 | $35,772,000 | $45,355,000 | $52,001,000 |
| Accumulated Depreciation | $-23,821,000 | $-22,401,000 | $-21,582,000 | $-32,836,000 |
| Gross PPE | $54,087,000 | $58,173,000 | $66,937,000 | $84,837,000 |
| Leases | $25,281,000 | $25,317,000 | $26,207,000 | $24,583,000 |
| Other Properties | $24,409,000 | $28,392,000 | $36,347,000 | $55,571,000 |
| Machinery Furniture Equipment | $4,397,000 | $4,464,000 | $4,383,000 | $4,683,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $147,551,000 | $50,553,000 | $62,881,000 | $29,312,000 |
| Non Current Deferred Revenue | - | - | $0 | $192,000 |
| Current Deferred Revenue | - | - | - | $24,000 |
| Duefrom Related Parties Current | - | - | - | $0 |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $238,499,000 | $-11,867,000 | $-29,485,000 | $-187,563,000 |
| Operating Activities | ||||
| Operating Cash Flow | $238,541,000 | $-11,535,000 | $-26,997,000 | $-186,991,000 |
| Cash Flow From Continuing Operating Activities | $238,541,000 | $-11,535,000 | $-26,997,000 | $-2,425,000 |
| Operating Gains Losses | $35,000 | $34,000 | $1,352,000 | $317,000 |
| Cash From Discontinued Operating Activities | - | - | $0 | $-184,566,000 |
| Investing Activities | ||||
| Capital Expenditure | $-42,000 | $-332,000 | $-2,488,000 | $-572,000 |
| Investing Cash Flow | $-105,284,000 | $12,284,000 | $-32,697,000 | $1,154,009,000 |
| Cash Flow From Continuing Investing Activities | $-105,284,000 | $12,284,000 | $-32,697,000 | $58,875,000 |
| Cash From Discontinued Investing Activities | - | - | $0 | $1,095,134,000 |
| Net Other Investing Changes | - | - | - | $2,709,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-4,034,000 | $-3,104,000 | $-199,551,000 | $-132,280,000 |
| Issuance Of Capital Stock | $20,000 | $99,000 | $0 | $0 |
| Financing Cash Flow | $-3,248,000 | $-2,497,000 | $-198,933,000 | $-758,806,000 |
| Cash Flow From Continuing Financing Activities | $-3,248,000 | $-2,497,000 | $-198,933,000 | $-738,617,000 |
| Net Common Stock Issuance | $-4,014,000 | $-3,005,000 | $-199,551,000 | $-132,280,000 |
| Common Stock Issuance | $20,000 | $99,000 | $0 | $0 |
| Cash From Discontinued Financing Activities | - | - | $0 | $-20,189,000 |
| Net Other Financing Charges | - | - | - | $24,464,000 |
| Other | ||||
| Income Tax Paid Supplemental Data | $27,884,000 | $109,000 | $24,000 | $117,966,000 |
| End Cash Position | $168,642,000 | $38,633,000 | $40,381,000 | $299,008,000 |
| Beginning Cash Position | $38,633,000 | $40,381,000 | $299,008,000 | $90,796,000 |
| Changes In Cash | $130,009,000 | $-1,748,000 | $-258,627,000 | $208,212,000 |
| Proceeds From Stock Option Exercised | $766,000 | $508,000 | $618,000 | $802,000 |
| Common Stock Payments | $-4,034,000 | $-3,104,000 | $-199,551,000 | $-132,280,000 |
| Net Investment Purchase And Sale | $-105,242,000 | $12,616,000 | $-31,722,000 | $54,872,000 |
| Sale Of Investment | $142,975,000 | $155,651,000 | $102,812,000 | $158,017,000 |
| Purchase Of Investment | $-248,217,000 | $-143,035,000 | $-134,534,000 | $-103,145,000 |
| Net PPE Purchase And Sale | $-42,000 | $-332,000 | $-975,000 | $1,294,000 |
| Purchase Of PPE | $-42,000 | $-332,000 | $-2,488,000 | $-572,000 |
| Change In Working Capital | $120,471,000 | $20,355,000 | $-8,340,000 | $42,350,000 |
| Change In Other Working Capital | $10,481,000 | $9,906,000 | $886,000 | $63,760,000 |
| Change In Other Current Liabilities | $-7,050,000 | $129,000 | $4,546,000 | $-1,549,000 |
| Change In Other Current Assets | $143,091,000 | $-296,000 | $-1,547,000 | $-8,226,000 |
| Change In Payables And Accrued Expense | $4,335,000 | $2,218,000 | $-7,089,000 | $-16,944,000 |
| Change In Accrued Expense | $4,009,000 | $1,468,000 | $-7,095,000 | $-15,332,000 |
| Change In Payable | $326,000 | $750,000 | $6,000 | $-1,612,000 |
| Change In Account Payable | $326,000 | $750,000 | $6,000 | $-1,612,000 |
| Change In Prepaid Assets | $-3,287,000 | $9,364,000 | $-4,447,000 | $8,029,000 |
| Change In Receivables | $-27,099,000 | $-966,000 | $-689,000 | $-2,720,000 |
| Changes In Account Receivables | $-27,099,000 | $-966,000 | $-689,000 | $-2,720,000 |
| Other Non Cash Items | $2,372,000 | $2,546,000 | $2,350,000 | $974,000 |
| Stock Based Compensation | $18,476,000 | $21,393,000 | $25,371,000 | $39,734,000 |
| Asset Impairment Charge | $0 | $4,513,000 | $0 | - |
| Deferred Tax | $-11,519,000 | $-7,573,000 | $3,207,000 | $0 |
| Deferred Income Tax | $-11,519,000 | $-7,573,000 | $3,207,000 | $0 |
| Depreciation Amortization Depletion | $2,811,000 | $3,615,000 | $4,256,000 | $7,024,000 |
| Depreciation And Amortization | $2,811,000 | $3,615,000 | $4,256,000 | $7,024,000 |
| Amortization Cash Flow | $-2,830,000 | $-2,509,000 | $-1,897,000 | $-681,000 |
| Amortization Of Intangibles | $-2,830,000 | $-2,509,000 | $-1,897,000 | $-681,000 |
| Depreciation | $5,641,000 | $6,124,000 | $6,153,000 | $7,705,000 |
| Gain Loss On Sale Of PPE | $35,000 | $34,000 | $1,352,000 | $-8,000 |
| Net Income From Continuing Operations | $105,895,000 | $-56,418,000 | $-55,193,000 | $-92,824,000 |
| Sale Of PPE | - | $0 | $1,513,000 | $1,866,000 |
| Repayment Of Debt | - | - | $0 | $-631,603,000 |
| Interest Paid Supplemental Data | - | - | $0 | $22,244,000 |
| Net Issuance Payments Of Debt | - | - | $0 | $-631,603,000 |
| Net Long Term Debt Issuance | - | - | $0 | $-631,603,000 |
| Long Term Debt Payments | - | - | $0 | $-631,603,000 |
| Change In Interest Payable | - | - | $0 | $-1,246,000 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Net Business Purchase And Sale | - | - | - | - |
| Sale Of Business | - | - | - | - |
| Earnings Losses From Equity Investments | - | - | - | - |
Fetched: 2026-06-15